J ALLERGY CLIN IMMUN:气道和血清生化相关的难治性中性粒细胞哮喘

2017-02-13 wangyanhong MedSci原创

尽管哮喘的诊断和管理有进步,许多患者仍控制不佳或者为难治性哮喘,难治性哮喘的机制尚未阐明。本研究探讨难治性哮喘中性粒细胞及其他生物标记物之间的关系

背景及目的:尽管哮喘的诊断和管理有进步,许多患者仍控制不佳或者为难治性哮喘,难治性哮喘的机制尚未阐明。本研究探讨难治性哮喘中性粒细胞及其他生物标记物之间的关系

方法:60例难治性哮喘(RA),30例非难治性哮喘(NRA)和20例健康受试者纳入本研究。对所有受试者进行全面评估:劳动力和肺功能测试,胸部CT和支气管肺泡灌洗液(BAL)。应用多因子检测试剂盒分析BAL和血清中一共244个生物分子及其相关的临床和其他实验室参数。

结果:RA和NRA的肺功能指标、支气管基底膜厚度和BAL中性粒细胞和淋巴细胞而非嗜酸性粒细胞有明显差异,BAL中性粒细胞与用力肺活量呈负相关,与年龄呈正相关。研究的244个生物分子中,其中BAL中52个,血清中14个,他们在各组间亦有明显差异。52个中有13个与BAL中性粒细胞相关。40% RA患者的BAL与病原微生物呈正相关,感染阴性的中性粒细胞性RA与血清中特定炎性生物标记物增多有关,这提示全身性炎症的存在。

结论:RA与气道中性粒细胞和促中性粒细胞生物分子增多有关,40% RA患者出现亚临床感染,这可能导致中性粒细胞性炎症。非感染的中性粒细胞性RA亚组与全身性炎症相关。

原文出处:

Alam, R., et al., Airway and Serum Biochemical Correlates of Refractory Neutrophilic Asthma. J Allergy Clin Immunol, 2017 Feb 2. doi: 10.1016/j.jaci.2016.12.963.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797034, encodeId=f9d31e97034ea, content=<a href='/topic/show?id=ecf922203c8' target=_blank style='color:#2F92EE;'>#中性粒细胞哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22203, encryptionId=ecf922203c8, topicName=中性粒细胞哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Nov 30 17:14:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296619, encodeId=22a812966193a, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328918, encodeId=e954132891839, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528335, encodeId=09b7152833506, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797034, encodeId=f9d31e97034ea, content=<a href='/topic/show?id=ecf922203c8' target=_blank style='color:#2F92EE;'>#中性粒细胞哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22203, encryptionId=ecf922203c8, topicName=中性粒细胞哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Nov 30 17:14:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296619, encodeId=22a812966193a, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328918, encodeId=e954132891839, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528335, encodeId=09b7152833506, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797034, encodeId=f9d31e97034ea, content=<a href='/topic/show?id=ecf922203c8' target=_blank style='color:#2F92EE;'>#中性粒细胞哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22203, encryptionId=ecf922203c8, topicName=中性粒细胞哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Nov 30 17:14:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296619, encodeId=22a812966193a, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328918, encodeId=e954132891839, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528335, encodeId=09b7152833506, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-15 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797034, encodeId=f9d31e97034ea, content=<a href='/topic/show?id=ecf922203c8' target=_blank style='color:#2F92EE;'>#中性粒细胞哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22203, encryptionId=ecf922203c8, topicName=中性粒细胞哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Thu Nov 30 17:14:00 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296619, encodeId=22a812966193a, content=<a href='/topic/show?id=29c82219e47' target=_blank style='color:#2F92EE;'>#中性粒细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22197, encryptionId=29c82219e47, topicName=中性粒细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328918, encodeId=e954132891839, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528335, encodeId=09b7152833506, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Feb 15 06:14:00 CST 2017, time=2017-02-15, status=1, ipAttribution=)]
    2017-02-15 freve

相关资讯

许文兵:难治性哮喘的诊疗策略

  近10年来,哮喘规范化治疗得到推广,多数哮喘患者的病情可缓解,但也有部分哮喘患者在经过正规治疗后病情仍无法控制。根据文献报告,约5%~10%的哮喘为难治性哮喘。   难治性哮喘的诊疗策略   北京协和医院呼吸科 许文兵   诊断 在诊断难治性哮喘前,须排除其他诊断(例如声带功能紊乱、上气道阻塞性疾病、复发性多软骨炎、气管淀粉样变性、慢性阻塞性肺病、反复误吸等),纠正哮喘加重因素(例如未确

Lancet Respir Med:CXCR2拮抗剂AZD5069对难治性哮喘没什么作用

气道中性粒细胞炎症是一些重症哮喘患者的病理特征之一;趋化因子受体CXCR2介导的刺激中性粒细胞向气道迁移。我们对不受控制的严重哮喘患者进行了研究,探究CXCR2拮抗剂AZD5069作为辅助治疗的有效性和安全性。 在这项多中心、随机、双盲、安慰剂对照、剂量探索试验中,我们招募了年龄在18岁或以上、病情不受控制的哮喘患者(长效β2受体激动剂、中剂量或大剂量吸入糖皮质激素联合治疗后也不能控制病情)